Silence Therapeutics

SLN: 468.00 -2.00 (-0.43%) delayed: 21 Feb 2020, 18:29

Trade now

Silence Therapeutics Fundamentals

Share Price Information

Name Silence Therapeutics
Epic SLN
Sector Biotechnology
ISIN GB00B9GTXM62
Activites Silence Therapeutics plc (formerly SR Pharma plc, formerly Stanford Rook Holdings plc) is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Index n/a

Key numbers

Latest Share price (p) 468.00 Net gearing (%) -45.43
Market capitalisation (£m) 347.96 Gross gearing (%) 9.85
Shares in issue (m) 78.37 Debt ratio 0.00
P/E ratio -16.95 Debt-to-equity ratio 0.00
Total dividends per share (p) 0.00 Assets / equity ratio 1.11
Dividend yield (%) 0.00 Price to book value 9.92
Dividend cover 0.00 ROCE (%) -58.56
Earning per share (p) -26.20 EPS growth (%) -1,039.13
52-week high / low (p) 610.00 / 40.00 DPS growth (%) n/a

Results at a glance

Date Type Turnover (£m) Profit (£m) Basic EPS Currency
31 Dec 2018 Full Year 0 -18 -26.20 GBP
31 Dec 2017 Full Year 0 -2 -2.30 GBP
31 Dec 2016 Full Year 1 -8 -12.10 GBP

Dividend history

Period Ex-date Pay-date Net dividend Currency Total for year

Contact details

Company name Silence Therapeutics
Address 1 Lyric Square, Hammersmith, London W6 0NB.
Telephone +44 (0)203 700 9711
Website http://www.silence-therapeutics.com/

Advisors

Company's broker Canaccord Genuity Limited
Company's joint broker n/a
NOMAD Canaccord Genuity Limited
Registrar Link Asset Services
Auditors KPMG Audit
Solicitors Fasken Martineau Stringer Saul LLP

Directors

Appointed Director Position
17 Jul 2018 Dr David Horn Solomon Chief Executive Officer
25 Apr 2019 Iain Gladstone Ross Non-Executive Chairman
25 Apr 2019 James Lawrence Ede-Golightly Non-Executive Director
12 Nov 2015 Alistair William Gray Non-Executive Director
21 Jun 2018 David Jakob Lemus Non-Executive Director
29 Jul 2019 Dr Steven Joseph Romano Non-Executive Director

Company financials

Assets (£m) 2018 2017 2016
Reporting date 31 Dec 2018 31 Dec 2017 31 Dec 2016
Tangible assets 1 1 1
Intangible asssets and goodwill 8 8 8
Investments and other non-current assets 0 0 5
Total non-current assets 9 9 14
Inventory / work in progress 0 0 0
Trade and other receivables 0 1 1
Cash and equivalents 21 43 39
Other current assets and asset held for resale 8 2 2
Total of all assets 39 55 56
Liabilities (£m) 2018 2017 2016
Short term liabilities 4 3 2
Long term liabilities 0 0 0
Other liabilites / pension etc 0 0 0
Total of all liabilities 4 3 2
Net assets (£m) 2018 2017 2016
Net assets 35 52 54
Equity (£m) 2018 2017 2016
Share capital 4 4 3
Minority interests 0 0 0
Retained earnings -134 -116 -116
Share premium account 0 0 0
Other equity 165 165 167
Total equity 35 52 54
Cash Flow (£m) 2018 2017 2016
Cash from operating activities -17 -10 -10
Cashflow before financing -22 3 -15
Increase / decrease in Cash -21 3 -15
Income (£m) 2018 2017 2016
Turnover 0 0 1
Cost of sales 0 0 0
Gross profit 0 0 0
Operating profit -21 -14 -12
Pre-tax profit -21 -4 -10
Profit / loss for the year -18 -2 -8